HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Francesca Spinella Selected Research

ZD4054

10/2012The endothelin A receptor and epidermal growth factor receptor signaling converge on β-catenin to promote ovarian cancer metastasis.
4/2011Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells.
6/2010Combination therapy of zibotentan with cisplatinum and paclitaxel is an effective regimen for epithelial ovarian cancer.
2/2009Beta-arrestin links endothelin A receptor to beta-catenin signaling to induce ovarian cancer cell invasion and metastasis.
7/2007Combined targeting of endothelin A receptor and epidermal growth factor receptor in ovarian cancer shows enhanced antitumor activity.
7/2007ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo.
6/2006ZD4054, a potent endothelin receptor A antagonist, inhibits ovarian carcinoma cell proliferation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Francesca Spinella Research Topics

Disease

36Neoplasms (Cancer)
06/2020 - 03/2002
23Carcinoma (Carcinomatosis)
04/2011 - 03/2002
17Ovarian Neoplasms (Ovarian Cancer)
12/2014 - 08/2002
8Melanoma (Melanoma, Malignant)
04/2014 - 02/2004
7Hypoxia (Hypoxemia)
11/2014 - 08/2002
6Neoplasm Metastasis (Metastasis)
11/2014 - 08/2002
6Carcinogenesis
06/2010 - 12/2005
5Ovarian Epithelial Carcinoma
12/2014 - 06/2010
3Aneuploidy (Aneuploid)
06/2017 - 04/2016
2Colorectal Neoplasms (Colorectal Cancer)
06/2020 - 04/2020
2Breast Neoplasms (Breast Cancer)
04/2014 - 01/2013
2Kaposi Sarcoma (Kaposi's Sarcoma)
08/2008 - 08/2003
2Ascites
06/2006 - 08/2002
1Squamous Cell Carcinoma of Head and Neck
09/2020
1Head and Neck Neoplasms (Head and Neck Cancer)
09/2020
1Chromosome Aberrations (Chromosome Abnormalities)
06/2017
1Inborn Genetic Diseases (Disease, Hereditary)
01/2017
1Endometrial Neoplasms (Endometrial Cancer)
08/2008
1Brain Neoplasms (Brain Tumor)
08/2008

Drug/Important Bio-Agent (IBA)

32Endothelin-1 (Endothelin 1)IBA
11/2014 - 03/2002
16Endothelin A ReceptorIBA
12/2014 - 05/2003
15Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
06/2020 - 08/2002
11Endothelins (Endothelin)IBA
04/2014 - 07/2004
9Proteins (Proteins, Gene)FDA Link
06/2020 - 08/2002
7ZD4054IBA
10/2012 - 06/2006
7AtrasentanIBA
04/2006 - 08/2002
6Messenger RNA (mRNA)IBA
06/2006 - 08/2002
5Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
04/2014 - 03/2002
5Paclitaxel (Taxol)FDA LinkGeneric
06/2010 - 03/2002
4Peptide Hydrolases (Proteases)FDA Link
09/2020 - 08/2002
4Vascular Endothelial Growth Factor CIBA
04/2014 - 03/2009
4G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA
03/2013 - 08/2008
4Endothelin Receptors (Endothelin Receptor)IBA
03/2013 - 08/2002
4ErbB Receptors (EGF Receptor)IBA
10/2012 - 11/2004
4Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA
02/2007 - 07/2004
4ProstaglandinsIBA
02/2007 - 07/2004
3Angiogenesis Inducing Agents (Angiogenesis Factor)IBA
03/2014 - 08/2002
3Endothelin B ReceptorIBA
06/2010 - 02/2004
3beta CateninIBA
02/2009 - 11/2004
3Mitogen-Activated Protein KinasesIBA
07/2007 - 11/2004
3Peptides (Polypeptides)IBA
11/2004 - 03/2002
3Connexin 43 (Connexin43)IBA
11/2004 - 10/2003
2Cell-Free Nucleic AcidsIBA
06/2017 - 04/2016
2dichlorobis(azomycin)platinum IIIBA
06/2017 - 04/2016
2ArrestinIBA
12/2014 - 11/2014
2Prolyl Hydroxylases (Prolyl Hydroxylase)IBA
11/2014 - 06/2010
2Conditioned Culture MediaIBA
04/2014 - 04/2014
2LectinsIBA
04/2014 - 01/2013
2Carrier Proteins (Binding Protein)IBA
04/2014 - 01/2013
2Small Interfering RNA (siRNA)IBA
04/2014 - 03/2009
2Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA
03/2014 - 03/2013
2LigandsIBA
03/2013 - 11/2004
2Vascular Endothelial Growth Factor Receptor-3 (Flt 4)IBA
03/2013 - 10/2012
2Gefitinib (Iressa)FDA Link
10/2012 - 07/2007
2Matrix Metalloproteinases (MMPs)IBA
10/2012 - 11/2004
2beta-ArrestinsIBA
08/2010 - 02/2009
2integrin-linked kinaseIBA
08/2010 - 04/2006
2taxaneIBA
06/2010 - 05/2003
2Growth Factor ReceptorsIBA
02/2009 - 02/2007
2Caspase 3 (Caspase-3)IBA
07/2007 - 06/2006
2Endothelin-3 (Endothelin 3)IBA
02/2007 - 11/2004
2epigallocatechin gallate (epigallocatechin-3-gallate)IBA
06/2006 - 06/2006
2TeaIBA
06/2006 - 06/2006
2PolyphenolsIBA
06/2006 - 06/2006
2Cadherins (E-Cadherin)IBA
12/2005 - 11/2004
2Dinoprostone (PGE2)FDA Link
11/2004 - 11/2004
2A 192621IBA
11/2004 - 02/2004
2Cyclooxygenase 1IBA
11/2004 - 07/2004
2cyclo(Trp-Asp-Pro-Val-Leu)IBA
08/2002 - 03/2002
1MicroRNAs (MicroRNA)IBA
09/2020
1Biomarkers (Surrogate Marker)IBA
06/2020
1Circulating Tumor DNAIBA
04/2020
1Prostaglandins DIBA
01/2017
1Aligeron (AS 2)IBA
04/2016
1macitentanIBA
12/2014
1Monoclonal AntibodiesIBA
04/2014
1Glycoproteins (Glycoprotein)IBA
04/2014
1AntibodiesIBA
04/2014
1Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA
03/2014
1Biological ProductsIBA
09/2013
1Vascular Endothelial Growth Factor DIBA
03/2013
1Fibronectins (Fibronectin)IBA
01/2013
1CateninsIBA
10/2012
1BQ 788IBA
10/2012
1matrigelIBA
10/2012
1Neutralizing AntibodiesIBA
10/2012
1Glycogen Synthase Kinase 3 betaIBA
08/2010
1Phosphatidylinositols (Phosphatidylinositol)IBA
08/2010
1Pharmaceutical PreparationsIBA
06/2010
1PlatinumIBA
06/2010
1Glycogen Synthase KinasesIBA
02/2009
1Epidermal Growth Factor (EGF)IBA
07/2007
1Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA
07/2007
1Prostaglandins EIBA
02/2007
1CollagenIBA
06/2006
1AcidsIBA
06/2006
1IntegrinsIBA
04/2006

Therapy/Procedure

9Therapeutics
12/2014 - 03/2002
4Drug Therapy (Chemotherapy)
12/2014 - 12/2005
1Oral Administration
06/2006